Moreover, due to the high levels of PDE5 expression in the lung tissue and the proven vasodilatory activity of sildenafil, researchers rationally considered the drug’s possible therapeutic effect against pulmonary fibrosis, a complication of the COVID-19 disease [2,3,4]. Here, PDE5A is linked to pulmonary fibrosis.